Document is current
Any future updates will be listed below
-
Authors
Shenderov, Eugene http://orcid.org/0000-0001-9886-8542
De Marzo, Angelo M. http://orcid.org/0000-0003-4847-5307
Lotan, Tamara L. http://orcid.org/0000-0002-0494-9067
Wang, Hao http://orcid.org/0000-0001-6489-6940
Chan, Sin
Lim, Su Jin
Ji, Hongkai http://orcid.org/0000-0002-6480-0141
Allaf, Mohamad E.
Chapman, Carolyn
Moore, Paul A.
Chen, Francine
Sorg, Kristina
White, Andrew M.
Church, Sarah E. http://orcid.org/0000-0002-7194-4282
Hudson, Briana
Fields, Paul A. http://orcid.org/0000-0002-9608-6464
Hu, Shaohui
Denmeade, Samuel R.
Pienta, Kenneth J. http://orcid.org/0000-0002-4138-2186
Pavlovich, Christian P.
Ross, Ashley E.
Drake, Charles G.
Pardoll, Drew M.
Antonarakis, Emmanuel S. http://orcid.org/0000-0003-0031-9655
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30CA006973, P30CA006973, P30CA006973)
Prostate Cancer Foundation (YIA)
U.S. Department of Defense (W81XWH-19-1-0511, W81XWH‐18‐2‐0015, W81XWH-16-PCRP-CCRSA)
Macrogenics, Inc; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA58236)
Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 2 March 2023
First Online: 3 April 2023
Competing interests
: E.S. is a paid consultant to GT Biopharma, Guidepoint Global, FirstThought and GLG, and receives institutional research funding from MacroGenics, Inc. E.S.A. is a paid consultant/advisor to and/or received institutional research funding from Janssen, Astellas, Sanofi, Dendreon, Genentech, Pfizer, Amgen, Lilly, Bayer, Tokai, Clovis, AstraZeneca, Novartis and BMS; and patent and royalty rights from QIAGEN for AR-V7 in prostate cancer. P.M. and F.C. are employees of MacroGenics, Inc. and receive stock options. K.S., A.M.W., S.E.C. and B.H. are employees of NanoString Technologies Inc. and receive stock options. P.F. is an employee of Adaptive Biotechnologies and receives stock options. S.H. is an employee of CDI Labs and receives stock options. C.G.D. is an employee of Janssen and receives stock options. A.M.D.M. is a paid consultant to Merck and Cepheid and received institutional research funding from Janssen. The remaining authors report no competing interests.
